Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2026 | Balancing efficacy and toxicity risks when combining BTK and BCL2 inhibitors in patients with MCL

Yucai Wang • 10 Sep 2026
SOHO 2026
Mantle Cell Lymphoma BTK inhibitors Venetoclax
SYMPATICO

Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, comments on balancing the efficacy benefits of combining BTK inhibitors with BCL2 inhibitors against increased toxicity risks in patients with mantle cell lymphoma (MCL). Dr Wang highlights promising efficacy data from the SYMPATICO trial (NCT03112174), noting that combining these agents may improve progression-free survival but also likely increases the risk of cytopenia and infection, requiring closer patient monitoring. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yucai Wang

Sequential versus combination BR-BTKi therapy in MCL: which patients may benefit most
1:36
Sequential versus combination BR-BTKi therapy in MCL: which patients may benefit most
Yucai Wang • 10 Sep 2026
Challenges that remain in treating older patients with MCL & the value of tailored approaches
2:31
Challenges that remain in treating older patients with MCL & the value of tailored approaches
Yucai Wang • 18 Jun 2025
A Phase I/II trial of orelabrutinib, a covalent BTK inhibitor, in R/R MCL
3:23
A Phase I/II trial of orelabrutinib, a covalent BTK inhibitor, in R/R MCL
Yucai Wang • 18 Jun 2025
Rapid ramp-up dosing of bispecific antibodies targeting CD3 and CD20 for R/R LBCL
4:07
Rapid ramp-up dosing of bispecific antibodies targeting CD3 and CD20 for R/R LBCL
Yucai Wang • 18 Jun 2025

Related Videos

Relapse patterns and sequencing of CD19 CAR T-cell therapies in MCL: lessons from DLBCL and beyond
1:14
Relapse patterns and sequencing of CD19 CAR T-cell therapies in MCL: lessons from DLBCL and beyond
Elise Chong • 10 Sep 2026
Promising first real-world CIBMTR data for liso-cel in R/R mantle cell lymphoma
0:58
Promising first real-world CIBMTR data for liso-cel in R/R mantle cell lymphoma
Elise Chong • 10 Sep 2026
Sequential versus combination BR-BTKi therapy in MCL: which patients may benefit most
1:36
Sequential versus combination BR-BTKi therapy in MCL: which patients may benefit most
Yucai Wang • 10 Sep 2026
Sequencing covalent and non-covalent BTK inhibitors in MCL
0:57
Sequencing covalent and non-covalent BTK inhibitors in MCL
Nirav Niranjan Shah • 13 Jun 2026
The content of VJHemOnc is intended for healthcare professionals